Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis

Journal of Investigative Dermatology Symposium Proceedings

Volumn 1, Issue 1, 1996, Pages 97-101

  Majewski, Slawomir ^a   Skopinska, Magdalena ^a   Marczak, Maria ^a   Szmurlo, Andrzej ^a   Bollag, Werner ^a   Jablonska, Stefania ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; INTERLEUKIN 12; RETINOIC ACID;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; HELA CELL; HUMAN; MOUSE; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; DRUG SYNERGISM; HELA CELLS; HUMANS; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TRETINOIN;

EID: 0030112286     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Nature 361:657-660, 1993
2. Schule D, Umesono K, Mangelsdorf DJ, Bolado J, Pike JW, Evans RM: Jun-fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. Cell 61:497-504, 1990
3. Schradcr M, Bendik I, Becker-Andre M, Carlberg C: Interaction between retinoic acid and vitamin D signaling pathways. J Dial Chein 268:17830-17836, 1993
4. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans DM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446-449, 1992
5. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biol Sci 17:427-433, 1992
6. Hosomi J, Hosoi J, Abe S, Suda T: Regulation of terminal differentiation of cultured mouse epidermal cells by 1, 25-dihydroxyvitamin D3. Endocrinology 113:1950-1957, 1983
7. Murao SI, Gemmell MA, Callaham MF, Anderson NL, Huberman E: Control of macrophage cell differentiation in human promyelocytic HL-60 leukemia cells by 1, 25-dihydroxyvitamin D3 and phorbol-12-myristate-13-acetate. Cancer Res 43:4989-4996, 1983
8. Olson I, Gullberg U, Ivhed I, Nilsson K: Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1, 25-dihydroxycholecalcitoferol. Cancer Res 43:5862-5867, 1983
9. Smith EL, Walworth NC, Holick MF: Effect of 1, 25-dihydroxy vitamin D3 on morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dennatol 86:709-714, 1986
10. Kragballe K, Wildfang I-L: Calcipotriol (CM 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits prolifération of cultured human keratinocytes. Arch Dennatol Res 282:164-167, 1990
11. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic MR, Koeffler HP: l, 25-dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A 87:3929-3932, 1990
12. Chen TC, Person K, Wen-Wei L, Chen ML, Holik MF: The antiproliferative and differentia five activities of 1, 25-dihydroxyvitamin D3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. J Invest Dennatol 104:113-117, 1995
13. Frampton RJ, Omond SA, Eisman JA: Inhibition of human cancer cell growth by l, 25-dihydroxyvitamin D3 metabolites. Cancer Res 43:4443-4447, 1983
14. Eisman JA, Barkla DH, Tutton PJM: Suppression of in vivo growth of human cancer solid tumor xenografts by 1, 25-dihydroxyvitamin D3. Cancer Res 47:21-25, 1987
15. Eisman JA, Koga M, Sutherland RL, Barkla DH, Tutton PJM: 1, 25-dihydroxyvitamin D3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med 191:221-226, 1989
16. Abe J, Nakano T, Nishn Y, Matsumoto T, Ogata E, Ikeda K: A novel vitamin D3 analog, 22-oxa-l, 25-dihydroxyvitamin, D3 inhibits the growth of human breast cancer IK vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837, 1991
17. Colston KW, Chander SK, Mackay AG, Coombes RC: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Phannacol 44:693-702, 1992
18. Cross HS, Pavelka M, Slavik J, Peterlik M: Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer lust 84:1355-1357, 1992
19. Koga M, Sutherland RL: Retinoic acid acts synergistically with 1, 25-dihydroxyvitamin D3 or antioestrogen to inhibit T47D human breast cancer proliferation. J Steroid Biochem Mol Biol 39:455-460, 1991
20. Nakaya K, Deguchi Y, Chou S, Nakamura Y: Combination differentiarioninducer therapy for leukemic cells in mice. Cancer J 4:108-113, 1991
21. Defacque H, Domand J, Gommes T, Cabane S, Sevilla C, Marti J: Different combinations of retinoids and vitamin D3 analogs efficiently promote growth inhibition and differentiation of myelomonocytic leukemia cell Unes. J Pharmacol Exp Ther 271:193-199, 1994
22. Bollag W, Majewski S, Jablonska S: Biological interactions of retinoids with cytokines and vitamin D analogs as a basis for cancer combination chemotherapy. In: Livrea MA, Vidaldi G (eds.). Retinoids: From Basic Scietice to Clinical Application. Birkliauser Verlag, Basel, 1994, pp 267-280
23. Bollag W, Majewski S, Jablonska S: Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia 8:1453-1457, 1994
24. Gullberg U, Nilsson E, Einhorn S, Olsson I: Combinations of Interferon gamma and retinoic acid or 1, 25-dihydroxy-cholecalcitoferol induce differentiation of the human leukemia cell line U-937. Exp Hcmatol 13:675-679, 1985
25. Kelsey SM, Makin HLJ, Macey MG, Newland AC: Gamma interferon augments functional and phenotypic characteristics of vitamin D3-induced monocytoid différenciation in the U937 human leukacmic cell line. Lenk Res 14:1027-1033, 1990
26. Trinclneri G, Rosen M, Perussia B: Induction of differentiation of human myeloid cell lines by tumor necrosis factor in cooperation with 1, 25-dihydroxyvitamin D3. Cancer Res 47:2236-2242, 1987
27. Testa U, Masciulli R, Tritarelli E, Pustorino R, Mariana G, Martucci R, Barbcri T, Camagna A, Valtcri M, Pcschle C: Transforming growth factor-beta potentiates vitamin D3-înduced terminal monocytic differentiation of human leukemic cell lines. J Jmmnnol 150:2418-2430, 1993
28. Zuckennan SH, Surprenant YM, Tang J: Synergistic effect of granulocytemacrophage colony-stimulating factor and 1, 25-dihydroxyvitamin D3 on the differentiation of the human monocytic cell line U937. Blood 71:619-624, 1988
29. Folkman J: Tumor angïogenesis: therapeutic implications. N Engl J Med 285:1182-1186, 1971
30. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6, 1990
31. Polvcrini PJ, Solt DB: Expression of the angiogcnic phenotype by a subpopulation of keratinocytes derived from 7, 12-dimcthyl-benz[a]anthracene-initiated hamster buccal pouch epithelium. Carcinogcnesis 9:117-122, 1988
32. Ziehe M, Gullino PM: Angiogencsis and neoplastic progression in vitro. J Natl Cancer lust 69:483-486, 1982
33. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Mature Med 1:27-31, 1995
34. Rastincjad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angïogenesis by a cancer suppressor gene. Cell 56:345-355, 1989
35. Bouck N: Tumor angiogencsis: the role of oncogenes and tumor suppressor genes. Cancer Cells 2:179-185. 1990
36. Liotta LA, Staag PS, Statler-Stevcnson WG: Cancer metastasis and angiogcnesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991
37. Van Mcir EG: Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 8:171-176, 1994
38. O'Reilly MS: Angiostatin: a novel inhibitor that mediates the suppression of métastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
39. Bamhill RL, Fandrey K, Levy MA, Mihm MC, Hyman B: Angiogenesis and tumor progression of melanoma, quantitation of vascularity in melanocystic nevi and cutaneous melanoma. Lab Invest 67:331-337, 1992
40. Graham CH, Rivers J, Kerbel RS, Stankicwicz KS, White WL: Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 145:510-514, 1994
41. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Boracchi P, Testolin A, Pozza F, Folkman J: Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous cell carcinoma, ïnt J Cancer 55:739-744, 1993
42. Guinehrieticre JM, Le Monique G, Gavoille A, Bahi J, Contesso G: Angiogencsis and risk of breast cancer in women with fibrocystic disease. J Nail Cancer Inst 86:635-636, 1994
43. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angtogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
44. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator of primary breast carcinoma, bit J Cancer 55:371-374, 1993
45. Brown L, Berse B, Jackman R, Tognazzi K, Guidi A, Dvorak H, Senger D, Connolly J, Schnitt S: Expression of vascular permeability factor (vascular endothenal growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
46. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkmanj: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993
47. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA: Relation of ncovasculature to metastasis of non-small-cell lung cancer. Lancet 340:145-146, 1992
48. Sillman F, Boycc J, Fruchter R: The significance of atypical vessels and neovascularization in cervical ncoplasia. Am J Obstet Gynecol 139:154-159, 1981
49. Li VW, Folkcrth RD, Watanabe H, Yu C, Rupnick M, Banics P, Scott KM. Black KM, Sallan SE, Folknian J: Microvcssel count and cerebrospinal fluid basic fibroblasts growth factor in children with brain tumors. Laufet 334:82-86, 1994
50. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvcstris F; Bone marrow angiogenesis and progression in multiple myeloma, lirj Haematol 87:503-508, 1994
51. Maïone TE, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. TiPS 11:457-461, 1990
52. Denekamp J: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196, 1993
53. Gottesmail MM: Report of a meeting: molecular basis of cancer therapy. J Natl Cancer Inst 86:1277-1285, 1994
54. Karp JE, Broder S: Molecular foundations of cancer: new targets for intervention. Nature Med 1:309-319, 1995
55. Ingber D, Fujita T, Kishimoto S, Katsuichi S, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555-557, 1990
56. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Inhibition of tumor cell-induced angiogenesis by retinoids, 1, 25-dihydroxyvitamin D3 and their combination. Cancer Lett 75:35-39, 1993
57. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W: Retinoids, intcrfcron alpha, 1, 25-dihydroxyvitamïn D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RARa mediates the antiangiogenic effect of retinoids. Cancer Lett 89:117-124, 1995
58. Majewski S, Polakowski I, Marczak M, Jablonska S: The effects of retinoids on lymphocyte- and transformed cell line-induced angiogenesis. Clin Exp Dennatol 2:317-318, 1986
59. Majewski S. Szmurlo A, Marczak M, Jablonska S, Bollag W: Syncrgistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogcmc effect on HPV-harboring tumor cell lines. Int J Cancer 57:81-85, 1994
60. Brunda MJ, Luistro L, Warrior RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor and antimctastatic activity of interlcukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
61. Banks RE, Patel PM, Selby PJ: Interleukin 12: a new clinical player in cytokinc therapy. Br J Cancer 71:655-659, 1995
62. Gately MK, Gublcr U, Brunda MJ, Nadcau RR, Anderson TD. Lipman JM, Sarmiento U: Intcrleukin-12: a cytokinc with therapeutic potential in oncology and infectious diseases. Ther Immunol 1:187-196, 1994
63. Majewski S, Tokarski G, Moskalewski S: Relationship between the hair growth cycle and the intensity of lymphocyte-induced angiogenesis in mouse skin. Arch Dcrmatol Res 277:77-78, 1985
64. Schncider-Maunoury S, Croissant O, Orth G: Integration of human papillomavirus type 16 DNA sequences: a possible early event in the progression of genital tumors. J Viral 61:3295-3298, 1987
65. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47:5155-5161, 1987
66. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995
67. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff IH: 13-cis retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992
68. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK: 13-fw retinoic acid and interferon alpha-2a effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-240, 1992
69. Majewski S, Skopinska M, Bollag W, Jablonska S: Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet 344:1510-1511, 1994